2023-08-11 16:36:24 ET
- Revelation Biosciences press release ( NASDAQ: REVB ): Q2 GAAP EPS of -$0.25.
- As of June 30, 2023, Revelation had $15.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022.
- The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities.
- Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through June of 2024.
For further details see:
Revelation Biosciences GAAP EPS of -$0.25